Alginate-Coated ZIF-8 Carrier for Intestinal C7 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug delivery systems struggle with maintaining optimal drug levels and targeted delivery in the treatment of type 2 diabetes, particularly in the intestines, where existing methods fail to provide sufficient drug solubility, stability, and controlled release, necessitating a safe and efficient controlled drug delivery system in the treatment of type 2 diabetes.
Innovation Solution
A pH-sensitive alginate coating for controlled release of an active compound in the intestines, utilizing the unique properties of MOFs, such as their coordinately unsaturated centers and large surface area, to enhance drug solubility, stability, and targeted delivery of Cycloheptylamine hydrochloride (C7) within a zeolitic imidazolate framework 8 (ZIF-8) for treating type 2 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug delivery systems are used, then drug administration is simple, but drug solubility and stability in the intestines are insufficient
Solution Approach 1:
The patent employs a composite delivery system consisting of ZIF-8 metal-organic framework encapsulating the drug cycloheptylamine hydrochloride, coated with pH-sensitive sodium alginate. This composite structure combines the high surface area and porosity of MOFs for drug loading with the pH-responsive properties of alginate for controlled intestinal release, thereby improving drug solubility and stability while enabling targeted delivery.
Solution Approach 2:
ZIF-8, a metal-organic framework with inherent porosity and large surface area, is utilized as the core carrier for drug encapsulation. The porous structure provides extensive surface area for drug adsorption and facilitates controlled release through its coordinately unsaturated centers, enhancing drug solubility and stability in the gastrointestinal environment.
2Reliability
If conventional drug delivery systems are used, then the system is simple to manufacture, but targeted delivery to the intestines is insufficient
Solution Approach 1:
The patent utilizes pH-sensitive sodium alginate coating that responds to changes in pH parameters along the gastrointestinal tract. The coating remains intact in the acidic stomach environment (pH 1.5-3.5) but dissolves at the higher pH of the intestines (pH 6.0-7.5), enabling passive targeted delivery to the intestinal site without complex active targeting mechanisms.
Solution Approach 2:
The pH-sensitive alginate coating acts as an intermediary layer between the ZIF-8 drug carrier and the gastrointestinal environment. This intermediary provides pH-responsive controlled release, protecting the drug in the stomach and facilitating its release in the intestines, thereby achieving targeted delivery through a relatively simple manufacturing process.
3Reliability
If conventional drug delivery systems are used, then drug release is immediate, but controlled release in the intestines is insufficient
Solution Approach 1:
The delivery system exhibits periodic action by remaining stable during gastric passage and then releasing the drug periodically upon encountering intestinal pH conditions. The pH-sensitive alginate coating delays release until the appropriate anatomical location is reached, providing controlled release over the appropriate time frame for intestinal absorption.
Solution Approach 2:
The system transitions from a stable, non-releasing state in the acidic stomach to a dynamic releasing state in the basic intestinal environment. The pH-sensitive alginate coating dynamically responds to environmental pH changes, transforming from an intact protective barrier to a dissolved release mechanism, thereby enabling controlled release at the target site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively stabilizes C7 in the acidic stomach environment and releases it in the basic pH of the intestines, enhancing drug solubility and stability, thereby improving therapeutic outcomes in diabetes management.
Implementation Method 1
a pH-sensitive sodium alginate coating for controlled release at a basic pH
Implementation Method 2
the coating comprises a Metal-Organic Framework (MOF), wherein the MOF comprises a zeolitic imidazolate framework 8 (ZIF-8), wherein the basic pH ranges from about 5.7 to about 7.4
Implementation Method 3
utilizing the unique properties of MOFs, such as their coordinately unsaturated centers and large surface area, to enhance drug solubility
Implementation Method 4
encapsulation of Cycloheptylamine hydrochloride (C7) within a ZIF-8 MOF
Data Source
AI summary
A novel controlled drug delivery system (DDS) for treating type 2 diabetes that combines an active compound comprising Cycloheptylamine hydrochloride (C7), an oral antihyperglycemic agent for treating type II diabetes, within an alginate-coated Metal-Organic Framework (MOF) structure, ZIF-8 (C7-ZIF-8@Alginate). The system enhances drug solubility, stability, and controlled release of C7 by utilizing the unique properties of MOFs, such as their coordinately unsaturated centers and large surface area, thus enhancing the drug's effectiveness, leading to improved patient care.